Bonova Tablet

About Bonova 150 mg Tablet

Bonova 150 mg tablet is a bisphosphonate medicine whose generic name is ibandronic acid. It is used to treat osteoporosis after menopause and to lower the chance of broken bones in people with this condition.

There are 13 brands of Ibandronic Acid listed in Bangladesh. 10 of them have a lower unit price than Bonova. The lowest listed price is Bondrix 150 mg Tablet at ৳ 400.00 per unit.

What is Bonova 150 mg Tablet?

Bonova 150 mg tablet is a bisphosphonate preparation made by Radiant Pharmaceuticals Ltd. Its active ingredient is ibandronic acid, which works by slowing the breakdown of bone. It is prescribed for postmenopausal osteoporosis, where the doctor may confirm low bone mass with or without a previous osteoporotic fracture. The tablet comes in a kit pack. Ibandronic acid is a potent inhibitor of bone resorption. Treatment aims to reduce the risk of fractures. The doctor confirms the diagnosis and decides whether this medicine is suitable. Do not start or stop it without medical advice.

Uses of Bonova

Bonova is used to treat osteoporosis in women after menopause and to reduce the risk of fractures. The diagnosis may be based on low bone mass and a past osteoporotic fracture, or on low bone mass alone when no fracture has been documented. It is not a general tonic for bone strength and should only be taken when a doctor has diagnosed osteoporosis and prescribed it for you.

How to use Bonova

Take Bonova exactly as your doctor tells you, and do not change the dose or course yourself. Swallow the tablet whole with a full glass of plain water while sitting or standing upright. Do not take it with any drink other than plain water, and do not lie down afterwards, as your doctor advises. The doctor will tell you when in the day to take it and how to fit it around food, drink and other medicines. Ask your pharmacist if you are unsure.

Side effects of Bonova

Common side effects of ibandronic acid include indigestion, nausea, diarrhoea, stomach pain, muscle aches, headache and dizziness. Tell your doctor or pharmacist if any of these bother you or do not settle. Some people may have other reactions. Seek medical advice promptly if you have severe stomach or chest symptoms, trouble swallowing, or any unusual problem after taking it. Do not treat side effects with other medicines on your own without asking a healthcare professional first.

Safety and precautions

Do not take Bonova if you are allergic to ibandronic acid or any ingredient of the tablet. It is not for people with uncorrected low calcium levels or with certain oesophageal problems that slow the passage of food, or for anyone who cannot sit or stand upright for the period the doctor requires. Tell your doctor about stomach or swallowing problems before starting. Low calcium and other mineral problems should be treated first, and calcium and vitamin D intake matters. Bonova should not be used in pregnancy; breastfeeding women should ask the doctor before use. Anyone who is pregnant, may be pregnant or is breastfeeding should speak to the doctor first.

Frequently asked questions

What is the price of Bonova 150 mg tablet?

The listed price is ৳ 2507.52. Prices can change, so check the current price on the product listing or ask your pharmacy. Your pharmacist can also explain what the kit contains and any dispensing charges that may apply.

Which medicines may interact with Bonova?

Calcium supplements, antacids and some oral medicines containing aluminium, magnesium or iron can interfere with how ibandronic acid is absorbed. The doctor will tell you how to space these apart from Bonova. Always tell your doctor and pharmacist about every medicine, supplement and vitamin you take.

What is Bonova used for and what kind of medicine is it?

Bonova is a bisphosphonate preparation containing ibandronic acid. It is used to treat postmenopausal osteoporosis and to reduce the risk of fractures. The doctor confirms the diagnosis before prescribing it. It is not a painkiller and is not meant for general bone strengthening without a diagnosis.

Is Bonova safe in pregnancy or breastfeeding?

Bonova should not be used during pregnancy. If you are breastfeeding, ask your doctor before using it, because a decision is needed on whether it is appropriate for you. Tell your doctor if you are pregnant, think you may be pregnant, or are planning a pregnancy.

Indications

Ibandronic acid is indicated for the treatment of postmenopausal osteoporosis, to reduce the risk of fractures.

Treatment of Osteoporosis: Osteoporosis may be confirmed by the finding of low bone mass (T-score <-2.0 SD) and the presence or history of osteoporotic fracture, or a low bone mass (T-score <-2.5 SD) in the absence of documented pre-existing osteoporotic fracture.

Pharmacology

The pharmacodynamic action of ibandronic acid is inhibition of bone resorption. In vivo, ibandronic acid prevents experimentally induced bone destruction caused by cessation of gonadal function, retinoids, tumors or tumor extracts. In young (fast growing) rats, the endogenous bone resorption is also inhibited, leading to increased bone mass compared with untreated animals. Animal models confirm that ibandronic acid is a highly potent inhibitor of osteoclastic activity. In growing rats, there was no evidence of impaired mineralization even at doses greater than 5,000 times the dose required for osteoporosis treatment. The high potency and therapeutic margin of ibandronic acid allows for more flexible dosing regimens and intermittent treatment with long drug-free intervals at comparatively low doses.

Ibandronic acid is a highly potent bisphosphonate belonging to the nitrogen-containing group of bisphosphonates, which act on bone tissue and specifically inhibit osteoclast activity, It does not interfere with osteoclast recruitment. The selective action of ibandronic acid on bone tissue is based on the high affinity of this compound for hydroxyapatite, which represents the mineral matrix of the bone. Ibandronic acid reduces bone resorption, with no direct effect on bone formation. In postmenopausal women, it reduces the elevated rate of bone turnover towards premenopausal levels, leading to a progressive net gain in bone mass. Daily or intermittent administration of ibandronic acid results in reduced bone resorption as reflected in reduced levels of serum and urinary biochemical markers of bone turnover, increased BMD and a decreased incidence of fractures.

Dosage & Administration

The recommended dose of Ibandronic acid for treatment is one 150 mg film-coated tablet once a month. The tablet should preferably be taken on the same date each month. Ibandronic acid should be taken 60 minutes before the first food or drink (other than water) of the day or any other oral medication or supplementation (including calcium):
  • Tablets should be swallowed whole with a full glass of plain water (180 to 240 ml) while the patient is sitting or standing in an upright position. Patients should not lie down for 60 minutes after taking Ibandronic acid.
  • Plain water is the only drink that should be taken with Ibandronic acid. Please note that some mineral waters may have a higher concentration of calcium and therefore should not be used.
  • Patients should not chew or suck the tablet because of a potential for oropharyngeal ulceration. Patients should receive supplemental calcium or vitamin D if dietary intake is inadequate. In case a once-monthly dose is missed, patients should be instructed to take one Ibandronic Acid 150 mg tablet the morning after the tablet is remembered unless the time to the next scheduled dose is within 7 days. Patients should then return to taking their dose once a month on their originally scheduled date. If the next scheduled dose is within 7 days, patients should wait until their next dose and then continue taking one tablet once a month as originally scheduled. Patients should not take two 150 mg tablets within the same week.

Interaction

It is likely that calcium supplements, antacids and some oral medications containing multivalent cations (such as aluminium, magnesium, iron) are likely to interfere with the absorption of Ibandronic Acid. Therefore, patients must wait 60 minutes after taking Ibandronic Acid before taking other oral medications. Pharmacokinetic interaction studies in postmenopausal women have demonstrated the absence of any interaction potential with tamoxifen or hormone replacement therapy (estrogen). No interaction was observed when co-administered with melphalan/prednisolone in patients with multiple myeloma. In healthy male volunteers and postmenopausal women, i.v. ranitidine caused an increase in ibandronic acid bioavailability of about 20 %, probably as a result of reduced gastric acidity. However, since this increase is within the normal range of the bioavailability of ibandronic acid, no dosage adjustment is required when Ibandronic Acid is administered with H2-antagonists or other drugs which increase gastric pH.

In relation to disposition, no drug interactions of clinical significance are considered likely, since ibandronic acid does not inhibit the major human hepatic P450 isoenzymes and has been shown not to induce the hepatic cytochrome P450 system in rats. Furthermore, plasma protein binding is low at therapeutic concentrations and ibandronic acid is therefore unlikely to displace other drugs. Ibandronic acid is eliminated by renal excretion only and does not undergo any biotransformation. The secretory pathway appears not to include known acidic or basic transport systems involved in the excretion of other drugs. In a one-year study in postmenopausal women with osteoporosis (BM16549). the incidence of upper gastrointestinal events in patients concomitantly taking aspirin or NSAIDs was similar in patients taking Ibandronic Acid 2.5 mg daily or 150mg once monthly. Of over 1500 patients enrolled in study BM 16549 comparing monthly with daily dosing regimens of ibandronic acid, 14% of patients used histamine (H2) blockers or proton pump inhibitors. Among these patients, the incidence of upper gastrointestinal events in the patients treated with Ibandronic Acid 150 mg once monthly was similar to that in patients treated with Ibandronic Acid 2.5 mg daily.

Contraindications

Ibandronic Acid is contraindicated in patients with known hypersensitivity to ibandronic acid or to any of the excipients. Ibandronic Acid is contraindicated in patients with uncorrected hypocalcemia. As with all bisphosphonates indicated in the treatment of osteoporosis, pre-existing hypocalcemia needs to be corrected before initiating therapy with Ibandronic Acid. As with several bisphosphonates, Ibandronic Acid is contraindicated in patients with abnormalities of the esophagus which delay esophageal emptying such as stricture or achalasia. Ibandronic Acid is contraindicated in patients who are unable to stand or sit upright for at least 60 minutes.

Side Effects

The main side effects of ibandronic acid are dyspepsia, nausea, diarrhea, abdominal pain, muscle aches, headaches, dizziness.

Pregnancy & Lactation

Pregnancy: Ibandronic Acid should not be used during pregnancy. There was no evidence for a direct fetal toxic or teratogenic effect of ibandronic acid in daily orally treated rats and rabbits and there were no adverse effects on the development in F1 offspring in rats. Adverse effects of ibandronic acid in reproductive toxicity studies in the rat were those observed with bisphosphonates as a class. They include a decreased number of implantation sites, interference with natural delivery (dystocia), and an increase in visceral variations (renal pelvis ureter syndrome). Specific studies for the monthly regimen have not been performed. There is no clinical experience with Ibandronic Acid in pregnant women.

Nursing Mothers: Ibandronic Acid should not be used during lactation. In lactating rats treated with 0.08 mg/kg/day IV. ibandronic acid, the highest concentration of ibandronic acid in breast milk was 8.1 ng/ml and was seen in the first 2 hours after i.v. administration. After 24 hours, the concentration in milk and plasma was similar, and corresponded to about 5 % of the concentration measured after 2 hours.

Precautions & Warnings

Hypocalcemia and other disturbances of bone and mineral metabolism should be effectively treated before starting Ibandronic Acid therapy. Adequate intake of calcium and vitamin D is important in all patients. Orally administered bisphosphonates may cause local irritation of the upper gastrointestinal mucosa. Because of these possible irritant effects and a potential for worsening of the underlying disease, caution should be used when Ibandronic Acid is given to patients with active upper gastrointestinal problems (e.g. known Barrett’s esophagus, dysphagia, other esophageal diseases, gastritis, duodenitis or ulcers). Adverse experiences such as esophagitis, esophageal ulcers and esophageal erosions, in some cases severe and requiring hospitalization, rarely with bleeding or followed by esophageal stricture or perforation, have been reported in patients receiving treatment with oral bisphosphonates. The risk of severe esophageal adverse experiences appears to be greater in patients who do not comply with the dosing instruction and/or who continue to take oral bisphosphonates after developing symptoms suggestive of esophageal irritation. Patients should pay particular attention and be able to comply with the dosing instructions.

Physicians should be alert to any signs or symptoms signaling a possible esophageal reaction and patients should be instructed to discontinue Ibandronic Acid and seek medical attention if they develop dysphagia, odynophagia, retrosternal pain or new or worsening heartburn. While no increased risk was observed in controlled clinical trials there have been post-marketing reports of gastric and duodenal ulcers with oral bisphosphonate use, some severe and with complications. Since NSAIDs and bisphosphonates are both associated with gastrointestinal irritation, caution should be taken during concomitant medication with Ibandronic Acid. Osteonecrosis of the jaw (ONJ) has been reported in patients treated with bisphosphonates. Most cases have been in cancer patients undergoing dental procedures, but some have occurred in patients with postmenopausal osteoporosis or other diagnoses. Known risk factors for osteonecrosis of the jaw include a diagnosis of cancer, concomitant therapies (e.g., chemotherapy, radiotherapy, corticosteroids), and co-morbid disorders (e.g., anemia, coagulopathy, infection, pre-existing dental disease). Most reported cases have been in patients treated with bisphosphonates intravenously but some have been in patients treated orally. For patients who develop osteonecrosis of the jaw while on bisphosphonate therapy, dental surgery may exacerbate the condition. For patients requiring dental procedures, there are no data available to suggest whether discontinuation of bisphosphonate treatment reduces the risk of ONJ. Clinical judgment of the treating physician should guide the management plan of each patient based on individual benefit-risk assessment.

Overdose Effects

No specific information is available on the treatment of overdosage with ibandronic acid. However, oral overdosage may result in upper gastrointestinal adverse events, such as upset stomach, heartburn, esophagitis, gastritis, or ulcer. Milk or antacids should be given to bind ibandronic acid. Owing to the risk of esophageal irritation, vomiting should not be induced and the patient should remain fully upright.

Storage Conditions

Keep below 30°C temperature, away from light & moisture. Keep out of the reach of children.

Alternative brands of Ibandronic Acid

Other brands with the same generic name, cheapest first.

Bondrova IV Infusion

3 mg/3 ml

Ibandronic Acid

Healthcare Pharmaceuticals Ltd.

৳ 4410 ৳ 4500.00 2% off per unit

Medicine information is for reference only and is not medical advice. Always follow your doctor's prescription and check with a pharmacist.